

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



绿竹生物

LUZHU BIOTECH

Beijing Luzhu Biotechnology Co., Ltd.

北京綠竹生物技術股份有限公司

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2480)

**ELECTION OF THE NEW SESSION OF THE BOARD
ELECTION OF THE NEW SESSION OF THE SUPERVISORY BOARD
AND
PROPOSED AMENDMENTS TO THE INTERNAL RULES**

ELECTION OF THE NEW SESSION OF THE BOARD

The term of the fourth session of the board (the “**Board**”) of directors (the “**Director(s)**”) of Beijing Luzhu Biotechnology Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) will expire on 15 September 2025, and the Company has completed the nomination process of the Directors to be proposed for the fifth session of the Board.

Ms. JIANG Xianmin (蔣先敏), an executive Director, will retire from her office as an executive Director following the expiration of the term of the fourth session of the Board, and will not offer herself for re-election for the fifth session of the Board. Nevertheless, Ms. JIANG Xianmin will remain as an employee of the Group responsible for research and development matters. The Board has not received from Ms. JIANG Xianmin any disagreement between her and the Board relating to her retirement and there are no other matters relating to her retirement that need to be brought to the attention of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the shareholders of the Company (the “**Shareholders**”). The Company would like to take this opportunity to thank Ms. JIANG Xianmin for her valuable contributions to the Group.

Having considered the recommendations of the nomination committee of the Board, the Board has resolved to nominate Mr. KONG Jian (孔健), Ms. ZHANG Yanping (張琰平), and Ms. PENG Ling (彭玲) as the proposed executive Directors of the fifth session of the Board; Mr. MA Biao (馬彪) and Mr. KONG Shuangquan (孔雙泉) as the proposed non-executive Directors of the fifth session of the Board; and Mr. LEUNG Wai Yip (梁偉業), Mr. LIANG Yeshe (梁冶矢) and Ms. HOU Aijun (侯愛軍) as the proposed independent non-executive Directors of the fifth session of the Board (collectively, the “**Proposed Directors**”). Save for Ms. PENG Ling, the proposed successor to Ms. JIANG Xianmin, who is currently a supervisor and the chief technology officer of the Company, the Proposed Directors are all existing Directors. The biographical details of the Proposed Directors are set out in Appendix I to this announcement.

The above list of Proposed Directors will be submitted to the Shareholders for consideration and approval at the upcoming annual general meeting which is expected to be held in June 2025 (the “**AGM**”). In accordance with the articles of association of the Company (the “**Articles of Association**”), the term of office of the fifth session of the Board shall be three years. The term of office of each Proposed Director shall become effective on the date of approval of his/her appointment by the Shareholders at the AGM, or 15 September 2025 (i.e. the date of expiration of the term of the fourth session of the Board), whichever the later.

ELECTION OF THE NEW SESSION OF THE SUPERVISORY BOARD

The term of the fourth session of the board (the “**Supervisory Board**”) of supervisors (the “**Supervisor(s)**”) of the Company will expire on 15 September 2025, and both the Board and the Supervisory Board have resolved to nominate Ms. KONG Xi (孔茜), an existing Supervisor, as the proposed Shareholder representative Supervisor of the fifth session of the Supervisory Board (the “**Proposed Supervisor**”). The biographical details of the Proposed Supervisor are set out in Appendix II to this announcement.

The Proposed Supervisor will be submitted to the Shareholders for consideration and approval at the AGM. In accordance with the Articles of Association, the term of office of the fifth session of the Supervisory Board shall be three years. The term of office of the Proposed Supervisor shall become effective on the date of approval of her appointment by the Shareholders at the AGM, or 15 September 2025 (i.e. the date of expiration of the term of the fourth session of the Supervisory Board), whichever the later.

Among the members of the fifth session of the Supervisory Board, in addition to the above Proposed Supervisor, two employee representative Supervisors, namely, Mr. CHEN Liang (陳亮) (an existing Supervisor) and Ms. WANG Wei (王蔚), have been elected by the employees of the Company at the employees’ representative congress to join the fifth session of the Supervisory Board directly. The biographical details of the two employee representative Supervisors are also set out in Appendix II to this announcement.

PROPOSED AMENDMENTS TO THE INTERNAL RULES

In light of the requirements under the newly implemented Company Law of the People’s Republic of China (the “**PRC**”) and other relevant laws and regulations, the Board proposed to amend the Rules of Procedures of the General Meeting of Shareholders (《股東會議事規則》), the Rules of Procedures of the Meetings of the Board (《董事會議事規則》) and the Rules of Procedures of the Meetings of the Supervisory Board (《監事會議事規則》) (the “**Proposed Amendments to the Internal Rules**”). The Proposed Amendments to the Internal Rules are subject to the Shareholders’ approval at the AGM.

A circular containing, among other things, details of the Proposed Directors, the Proposed Supervisor and the Proposed Amendments to the Internal Rules, together with the notice of AGM, will be despatched to the Shareholders (if requested) and published on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (<http://www.luzhubiotech.com>).

By order of the Board
Beijing Luzhu Biotechnology Co., Ltd.
Mr. KONG Jian
Chairman and Executive Director

Hong Kong, April 16, 2025

As of the date of this announcement, the Board comprises Mr. KONG Jian, Ms. JIANG Xianmin and Ms. ZHANG Yanping as executive Directors; Mr. MA Biao and Mr. KONG Shuangquan as non-executive Directors; and Mr. LEUNG Wai Yip, Mr. LIANG Yeshe and Ms. HOU Aijun as independent non-executive Directors.

APPENDIX I – BIOGRAPHICAL DETAILS OF THE PROPOSED DIRECTORS

PROPOSED EXECUTIVE DIRECTORS

Mr. KONG Jian (孔健), aged 61, is an executive Director, the general manager of the Company, the chief scientist and leader of the research and development team of the Group, and the chairman of the Board, and is primarily responsible for the overall strategic development and key business decisions, including scientific research and production of the Group. He is one of the controlling shareholders of the Company. Mr. KONG joined the Company in July 2002 as the general manager. He is also the leader of the research and development team of the Group. He was appointed as a Director on September 11, 2008, and re-designated as an executive Director on June 18, 2022. He is also the director, legal representative and general manager of Luzhu Biopharmaceuticals (Zhuhai) Co., Ltd. (綠竹生物製藥(珠海市)有限公司) (“**Zhuhai Luzhu**”) and Luzhu Biologics (Beijing) Co., Limited (綠竹生物製品(北京)有限公司) (“**Beijing Luzhu**”), as well as the director of Luzhu Biologics (Hong Kong) Co., Limited (綠竹生物製品(香港)有限公司) (“**Hong Kong Luzhu**”). Zhuhai Luzhu, Beijing Luzhu and Hong Kong Luzhu are all wholly-owned subsidiaries of the Company.

Mr. KONG has over 36 years of experience in the biopharmaceutical industry. Mr. Kong has participated in the successful development of five vaccines which have been commercialized, including three types of bacterial polysaccharide conjugate vaccines and two multivalent meningococcal polysaccharide vaccines. In addition, Mr. Kong has developed vaccines and monoclonal antibodies under clinical investigation, including a recombinant herpes zoster vaccine, two monoclonal antibodies, a bispecific antibody and an inactivated enterovirus 71 vaccine. Prior to joining the Group, from October 1988 to 2002, he worked in the Beijing National Vaccine and Serum Institute of the Ministry of Health (衛生部北京生物製品研究所), a research institute primarily focused on microbiology and immunology research and productions of epidemic prevention products. He worked as the director of the Science and Technology Development Division (科技開發處處長) and manager of the immunodiagnostic laboratory (免疫診斷研究室主任) of the Beijing National Vaccine and Serum Institute of the Ministry of Health since October 2000, and was primarily responsible for scientific research of biological products. In March 2000, Mr. KONG was also accredited as a researcher in biomedical science at the Chinese Biologics Corporation (中國生物製品總公司), a state-owned institution primarily engaged in the research and production of vaccines and blood products.

Since April 2014, Mr. KONG was a limited partner holding approximately 1.65% interests in Beijing Baojin Jiaming Investment Management Center (Limited Partnership) (北京寶金嘉銘投資管理中心(有限合夥)), a limited liability partnership established in the PRC on June 12, 2012. Its business license was revoked on February 21, 2022 due to discontinuation of annual inspection filings by the general partner after cessation of business. As confirmed by Mr. KONG, the above partnership was solvent at the time of revocation of business license, there was no fraudulent act or misfeasance on the part of Mr. KONG leading to the revocation and he was not aware of any actual or potential claim that has been or will be made against him as a result of the revocation of business license of such company.

Mr. KONG obtained a bachelor degree in medicine from the School of Medicine in Shandong University (山東大學) (formerly known as the Shandong Medical University (山東醫學院)) in July 1985, and a postgraduate master degree in epidemiology from Tianjin Medical University (天津醫科大學) (formerly known as Tianjin School of Medicine (天津醫學院)) in September 1988.

Mr. KONG is the spouse of Ms. ZHANG Yanping, an executive Director, the uncle of Ms. KONG Xi, a Supervisor, and the father-in-law of Mr. LIU Siyu, one of the joint company secretaries of the Company and the secretary of the Board. Mr. KONG is also the general partner of Zhuhai Hengqin Luzhu Enterprise Management Partnership (LP) (珠海橫琴綠竹企業管理合夥企業(有限合夥)) (“**Hengqin Luzhu LP**”), the employee incentive platform of the Group and one of the controlling shareholders of the Company, holding approximately 0.97% interests therein as of the date of this announcement.

As of the date of this announcement, Mr. KONG Jian is beneficially interested in 58,294,513 H shares of the Company (“**H Shares**”), and deemed to be interested in 33,967,500 H Shares under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (“**SFO**”).

Ms. ZHANG Yanping (張琰平), aged 62, is an executive Director and the deputy general manager of the Company, primarily responsible for the overall finance and procurement of the Group. She was appointed as a Director on June 28, 2013 and was re-designated as an executive Director on June 18, 2022. She is also one of the controlling shareholders of the Company. Ms. ZHANG joined the Group in January 2004 as a manager of the research and development department, and is currently the deputy general manager of the Company, mainly in charge of the Group’s finance department. At the same time, Ms. ZHANG is also the head of the Group’s material department.

Ms. ZHANG has over 39 years of experience in biopharmaceutical industry and has extensive experience in quality control, quality assurance, and pre-clinical safety studies of biological products. She has also led the Group to obtain GMP certification for the Group’s Meningococcal Group A and C Polysaccharide Conjugate Vaccine and Group ACYW135 Meningococcal Polysaccharide Vaccine. Prior to joining the Group, from July 1985 to 2004, Ms. ZHANG worked as a technician at the Beijing National Vaccine and Serum Institute of the Ministry of Health (衛生部北京生物製品研究所), mainly participated in the preparation of intestinal bacteria and immunoglobulin diagnostic serum and the research of interferon- β antibody. In March 2000, Ms. ZHANG was appointed as a deputy researcher in biomedical science at the Chinese Biologics Corporation (中國生物製品總公司), a state-owned institution primarily engaged in the research and production of vaccines and blood products.

Ms. ZHANG obtained a bachelor degree in medicine from the School of Medicine in Shandong University (山東大學) (formerly known as the Shandong Medical University (山東醫學院)) in July 1985.

Ms. ZHANG is the spouse of Mr. KONG Jian, an executive Director, the aunt of Ms. KONG Xi, a Supervisor and the mother-in-law of Mr. LIU Siyu, one of the joint company secretaries of the Company and the secretary of the Board. As of the date of this announcement, Ms. ZHANG is (i) a limited partner of Hengqin Luzhu LP and holds approximately 27.61% interests therein; and (ii) the general partner of and holds approximately 7.15% interests in Zhuhai Luzhu Kangrui Enterprise Management Partnership (Limited Partnership) (珠海綠竹康瑞企業管理合夥企業(有限合夥)), which in turn is a limited partner of Hengqin Luzhu LP holding approximately 19.87% interests therein.

As of the date of this announcement, Ms. ZHANG Yanping is beneficially interested in 20,200,000 H Shares, and deemed to be interested in 72,062,013 H Shares under the SFO.

Ms. PENG Ling (彭玲), aged 44, was appointed as a Supervisor on July 19, 2019. She joined the Group in April 2015 and served as the deputy manager of the quality control department of the Group. Ms. PENG Ling also acted as a Director from November 2018 to July 2019 before her appointment as a Supervisor in July 2019. She has been appointed as the manager of the quality control department of the Group since March 2020. Since December 2021 she has also been appointed as the assistant to general manager of the Company. In April 2022, she has been appointed as the chief technology officer of the Company. Ms. PENG Ling is primarily responsible for leading the quality control department and supervising the operating and financial activities of the Company.

Ms. PENG Ling obtained a bachelor degree from Shandong Normal University (山東師範大學) majoring in chemistry in July 2003, and in June 2006, she further obtained a master degree in organic chemistry from the same university.

As of the date of this announcement, Ms. PENG Ling is the general partner of and holds approximately 20.69% interests in Beijing Luzhu Kangrui Enterprise Management Partnership (Limited Partnership) (北京綠竹康瑞企業管理合夥企業(有限合夥)) (“**Beijing Luzhu Kangrui**”), which in turn is a limited partner of Hengqin Luzhu LP holding approximately 40.67% interests therein.

As of the date of this announcement, Ms. PENG Ling is deemed to be interested in 12,307,500 H Shares under the SFO.

PROPOSED NON-EXECUTIVE DIRECTORS

Mr. MA Biao (馬彪), aged 61, is a non-executive Director, primarily responsible for providing management and strategic advice to the Group. He was nominated by Beijing Science Sun Pharmaceutical Co., Ltd. (北京賽升藥業股份有限公司) (“**Beijing Science Sun**”), as a Board representative and was appointed as a Director on August 2, 2019. Mr. MA Biao was re-designated as a non-executive Director on June 18, 2022.

Mr. MA Biao has over 25 years of experience in the pharmaceutical industry. From August 1999, Mr. MA Biao joined Beijing Science Sun, a company principally engaged in research, manufacture and sales of biological and biochemical pharmaceuticals and listed on the ChiNext board of the Shenzhen Stock Exchange (stock code: 300485) as the deputy general manager, and was appointed as its director and general manager in July 2001. Mr. MA Biao is the actual controller of Beijing Science Sun and holds approximately 49.51% of the issued shares of Beijing Science Sun as of the date of this announcement. He currently serves as the chairman of the board and the general manager of Beijing Science Sun, primarily responsible for overall management. From February 2018 to July 2023, Mr. MA served as a director of Beijing Eastern Biotech Co., Ltd. (北京東方百泰生物科技股份有限公司), a company principally engaged in the R&D and production of innovative antibody and macromolecular protein drugs, where he was an investor board representative primarily responsible for providing opinion and judgment to the board.

Mr. MA Biao obtained a master degree in biochemistry from Jilin University (吉林大學) in June 1989, and a doctorate degree in food science from the China Agricultural University (中國農業大學) in December 2008. Mr. MA Biao was also accredited as a researcher by Beijing Specialised Professions and Technique Titles Evaluation Committee (北京市高級專業技術職務評審委員會) in January 2017.

As of the date of this announcement, Mr. MA Biao is the actual controller of Beijing E-town Sun Fund Management Co., Ltd. (北京屹唐賽盈基金管理有限公司), which is the general partner and fund manager of Beijing Yizhuang Biological Medicine Investment Center (Limited Partnership) (北京亦莊生物醫藥併購投資中心(有限合夥)) (“**Beijing Yizhuang**”) and Beijing Yizhuang II Biological Medical Industry Investment Fund (Limited Partnership) (北京亦莊二期生物醫藥產業投資基金(有限合夥)) (“**Beijing Yizhuang II**”). Beijing Yizhuang, Beijing Yizhuang II and Beijing Science Sun are regarded as a group of substantial shareholders of the Company.

As of the date of this announcement, Mr. MA Biao is deemed to be interested in 51,721,196 H Shares under the SFO.

Mr. KONG Shuangquan (孔雙泉), aged 50, is a non-executive Director, primarily responsible for providing management and strategic advice to the Group. He was nominated by Beijing Yizhuang as a Board representative and was appointed as a Director on August 2, 2019. Mr. KONG Shuangquan was re-designated as a non-executive Director on June 18, 2022.

From July 2004 to July 2010, Mr. KONG Shuangquan worked at the research and development department of Beijing Science Sun primarily responsible for the development of pharmaceutical drug. From July 2010 to September 2011, Mr. KONG Shuangquan also worked at TianXinFu (Beijing) Medical Appliance Co., Ltd. (天新福(北京)醫療器材股份有限公司, formerly known as Beijing TianXinFu Medical Appliance Co., Ltd. (北京天新福醫療器材股份有限公司)), a company principally engaged in the production of medical equipment involving regenerated medical biomaterials, serving as a manager of the research and development technology department and primarily responsible for the company’s biomaterial product development. Subsequently, Mr. KONG Shuangquan re-joined Beijing Science Sun in September 2011, and he is currently the chief engineer of the research and development department of Beijing Science Sun, in charge of the company’s technology and product development. Mr. KONG Shuangquan is also currently a director and deputy general manager of Beijing Protein Innovation Co., Ltd. (北京華大蛋白質研發中心有限公司), an investment entity of Beijing Science Sun, where he is primarily responsible for the company’s daily operation and decisionmaking process. Beijing Huada Protein Research and Development Center Co., Ltd. is principally engaged in contract research, drug analysis and the provision of protein-based biologics services including protein expression and purification, recombinant protein, as well as antibody preparation and identification.

Mr. KONG Shuangquan obtained a master degree in microbiology and biochemical pharmacy from Jilin University (吉林大學) in June 2004. In November 2012, Mr. KONG Shuangquan was named as an assistant researcher by the Beijing Intermediate Professional Technical Position Appraisal Committee (北京中級專業技術職務評審委員會).

PROPOSED INDEPENDENT NON-EXECUTIVE DIRECTORS

Mr. LEUNG Wai Yip (梁偉業), aged 49, was appointed as an independent non-executive Director on March 30, 2023, primarily responsible for supervising and providing independent opinion to the Board.

Mr. LEUNG Wai Yip has more than 20 years of experience in audit and financial management. Prior to joining the Group, from March 2000 to August 2005, he acted consecutively as the auditor, senior auditor and manager in the assurance and advisory business services department of Ernst & Young. From May 2007 to December 2010, Mr. LEUNG Wai Yip served as the financial controller and the company secretary of Tiangong International Company Limited (listed on the Stock Exchange, stock code: 826), mainly responsible for the initial public offering of the group and post-listing financial management and investor relationships. He has been the chief financial officer and company secretary of Chaowei Power Holdings Limited (listed on the Stock Exchange, stock code: 951) since December 2010, mainly responsible for the company's financial management, overseas acquisition and financing and investor relationships. Mr. LEUNG Wai Yip also served as an independent non-executive director of Miko International Holdings Limited (listed on the Stock Exchange, stock code: 1247) from December 2013 to February 2016. Since April 2018, he has also been appointed as an independent non-executive director and chairman of the audit committee of HPC Holdings Limited (listed on the Stock Exchange, stock code: 1742).

In addition, Mr. LEUNG Wai Yip was a director of Coyoh Limited, a company incorporated in Hong Kong on 8 June 2009 which did not commence any business ever. On October 10, 2014, Coyoh Limited was dissolved by striking off under Section 744(3) of the Companies Ordinance, pursuant to which if the Registrar of Companies in Hong Kong has reasonable cause to believe that a company is not carrying on business or in operation, the Registrar of Companies in Hong Kong may strike the name of the company off the register after the expiration of a specified period. Mr. LEUNG Wai Yip confirmed that Coyoh Limited was solvent and did not carry out any business at the time of it being struck off. Mr. LEUNG Wai Yip also confirmed that he did not have any outstanding liabilities in relation to Coyoh Limited's being struck off and Coyoh Limited had no outstanding liabilities at the time of it being struck off.

Mr. LEUNG Wai Yip obtained a degree of bachelor of commerce from the University of Alberta in June 1998 and a degree of master of business administration from the Hong Kong University of Science and Technology in November 2010 respectively. He has been a member of the American Institute of Certified Public Accountants since December 2002, and an associate member of the Hong Kong Institute of Certified Public Accountants since May 2003.

Mr. LIANG Yeshi (梁冶矢), aged 75, was appointed as an independent non-executive Director on March 30, 2023, primarily responsible for supervising and providing independent opinion to the Board.

Mr. LIANG Yeshi has over 35 years of experience in the medical field. Since 1989, Mr. LIANG Yeshi joined the Peking University People's Hospital (北京大學人民醫院) and his last position was the deputy director of the neurosurgery department.

Mr. LIANG Yeshi was a supervisor of Beijing Zhuoyue Tonghua Advertising Co., Ltd. (北京卓越通華廣告有限責任公司) ("**Beijing Zhuoyue**"), a limited liability company established in the PRC on January 31, 2002. The business license of Beijing Zhuoyue was revoked on October 8, 2013 as it did not conduct annual inspection. As confirmed by Mr. LIANG Yeshi, he was not involved in the operation and management of Beijing Zhuoyue, and there was no fraudulent act or misfeasance on his part leading to the revocation. Further, as confirmed by Mr. LIANG Yeshi, Beijing Zhuoyue was solvent at the time of revocation of its business license, and Mr. LIANG Yeshi was not aware of any actual or potential claim that has been or will be made against him as a result of the revocation of business license of Beijing Zhuoyue.

Mr. LIANG Yeshi obtained a master degree in medicine from Tianjin Medical University (天津醫科大學) in September 1988.

Ms. HOU Aijun (侯愛軍), aged 59, was appointed as an independent non-executive Director on March 30, 2023, primarily responsible for supervising and providing independent opinion to the Board. Prior to joining the Group, from March 1992 to November 2009, she worked in the China Biotechnology Group Corporation (中國生物技術集團公司), a company principally engaged in the research and development of biological products and her last position was the deputy director of the research and development management department. She was mainly responsible for management of scientific research projects. In 2009, she joined China National Pharmaceutical Group Co., Ltd. (中國醫藥集團有限公司) (formerly known as China National Pharmaceutical Group Corporation (中國醫藥集團總公司)), a company principally engaged in the distribution, research and development and production of health-related products. She worked as the deputy manager of the research development management department (研發管理部). Subsequently in July 2010, she was appointed as the secretary general of the science and technology committee of the company, and in March 2018 she was further appointed as the deputy manager of the science and technology committee. In July 2018, she was further appointed to act as the deputy director of policy research office of the China National Pharmaceutical Group Co., Ltd. concurrently, mainly responsible for assisting its board of directors in strategic decision-making process with reference to national policies and regulations in the medical industry.

Ms. HOU Aijun obtained a bachelor degree in applied biochemistry from the Department of Biology of the Peking University (北京大學) in July 1987.

OVERVIEW

According to the Articles of Association, each term of office of a Director is three years and subject to the provisions of the Articles of Association, a Director shall be eligible to be re-elected upon the expiry of the term of office.

The Company will enter into or renew the service contract with each of the Proposed Directors upon the Shareholders' approval of their appointments. The executive Directors will not receive any director's fees but will receive corresponding remuneration in accordance with their positions in the Group. The details of their remuneration will be disclosed in the annual report of the Company. The non-executive Directors will not receive any remuneration from the Company during their terms of office. Each of the independent non-executive Director will receive an annual allowance of RMB160,000 (before tax) from the Company during his/her term of office.

Save as disclosed in this announcement, each of the Proposed Directors has confirmed that, as of the date of this announcement: (i) he/she has not held any other directorships in any listed companies, in Hong Kong or overseas, in the last three years, nor any other positions within the Group; (ii) he/she does not have any relationship with any Directors, Supervisors, senior management, substantial Shareholders or controlling Shareholders of the Company; (iii) he/she does not have any interests or short positions in the shares, underlying shares or bonds of the Company or its associated corporation(s) within the meaning of Part XV of the SFO; and (iv) there is no other information relating to his/her appointment that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules and there is no other matter that needs to be brought to the attention of the Shareholders or the Stock Exchange.

APPENDIX II – BIOGRAPHICAL DETAILS OF THE PROPOSED SHAREHOLDER REPRESENTATIVE SUPERVISOR AND THE EMPLOYEE REPRESENTATIVE SUPERVISORS

PROPOSED SHAREHOLDER REPRESENTATIVE SUPERVISOR

Ms. KONG Xi (孔茜), aged 32, was appointed as a Supervisor on July 21, 2014. She has been working as a technician in the quality control department of the Group since July 2013. Ms. KONG Xi is mainly responsible for supervising the operating and financial activities of the Company.

Ms. KONG Xi obtained a bachelor degree in bioengineering in June 2013 from Huaqiao University (華僑大學).

Ms. KONG Xi is the niece of Mr. KONG Jian and Ms. ZHANG Yanping, the executive Directors. Ms. KONG Xi is also a limited partner of Beijing Luzhu Kangrui, and holds approximately 3.82% interests therein as of the date of this announcement.

As of the date of this announcement, Ms. KONG Xi is beneficially interested in 550,000 H Shares.

EMPLOYEE REPRESENTATIVE SUPERVISORS

Mr. CHEN Liang (陳亮), aged 45, was appointed as a Supervisor on April 26, 2022. He joined the Group's human resources and administration department in August 2021 as a manager. Mr. CHEN Liang is mainly responsible for supervising the operating and financial activities of the Company.

Prior to joining the Group, Mr. CHEN Liang worked as the chief executive officer for Beijing Jieyatai Zhongsheng Automobile Sales Co., Ltd. (北京捷亞泰中盛汽車銷售有限公司), a company primarily engaged in car sales, where he was primarily responsible for administration and human resource management.

Mr. CHEN Liang obtained a bachelor degree in law in July 2016 from Beihang University (北京航空航天大學) through attending long distance learning courses. He also obtained the professional qualifications of senior vocational management professional (level 1) (高級職業經理人(一級)) and the senior human resources management specialist (level 1) (高級人力資源管理師(一級)) in October 2015, and the professional qualification of safety evaluation professional (level 1) (安全評價師(一級)) in December 2018 from the Ministry of Human Resources and Social Security of the PRC (中華人民共和國人力資源和社會保障部).

As of the date of this announcement, Mr. CHEN Liang is a limited partner of Beijing Luzhu Kangrui, and holds approximately 3.98% interests therein.

As of the date of this announcement, Mr. CHEN is beneficially interested in 400 H Shares.

Ms. WANG Wei (王蔚), aged 44, joined the finance department of the Group in August 2021 as an accountant, and is primarily responsible for accounting and tax filing of the Group.

Ms. WANG has over 20 years of working experience in accounting and finance. Prior to joining the Group, from July 2002 to November 2008, Ms. WANG worked at Jinan Jin Cai Financial Management Consulting Co., Ltd. (濟南金財財務管理諮詢有限公司), an accounting and financial consulting company, as an accountant, and was mainly responsible for accounting and tax filing. Ms. WANG then worked as an accountant at Shandong Huatai Manor Garden Co., Ltd. (山東華泰莊園園林有限公司), a construction and engineering service provider, and Gan & Lee Pharmaceutical Co., Ltd. (甘李藥業股份有限公司), a pharmaceutical company listed on the Shanghai Stock Exchange (stock code: 603087), from November 2008 to August 2011 and September 2011 to July 2014, respectively, where she was mainly responsible for accounting, tax filing and information coordination and management in connection with initial public offering. Ms. WANG then worked at Dream Castle (Tianjin) E-commerce Co., Ltd. (夢想城堡(天津)電子商務有限公司), an e-commerce trading company, from December 2014 to March 2017 as its accounting and settlement supervisor, and was mainly responsible for transaction settlement with various e-commerce platforms and financial analysis. From March 2017 to June 2021, Ms. WANG worked as a finance manager in Beijing Fast Track Network Co., Ltd. (北京快道網路有限公司), an online service platform operator, and was mainly responsible for devising and implementing financial control system, budgeting, accounting and capital and tax management.

Ms. WANG obtained a diploma in accounting from Shandong Economics College (山東經濟學院) in July 2002 and a bachelor's degree in accounting in January 2008 from the same college. Ms. WANG also obtained the professional qualification of intermediate accountant (中級會計師) from the Beijing Municipal Human Resources and Social Security Bureau (北京市人力資源及社會保障局) in September 2015, and the professional qualification of senior management accountant (高級管理會計師) from the China Association of Chief Financial Officers (中國總會計師協會) in November 2022.

As of the date of this announcement, Ms. WANG is a limited partner of Beijing Luzhu Kangrui, and holds approximately 0.77% interests therein.

OVERVIEW

According to the Articles of Association, each term of office of a Supervisor is three years and subject to the provisions of the Articles of Association, a Supervisor shall be eligible to be re-elected upon the expiry of the term of office.

The Company will enter into or renew the service contract with each of Mr. CHEN Liang, Ms. WANG Wei and Ms. KONG Xi (upon the Shareholders' approval of her appointment). Such persons will not receive any supervisor's fees but will receive corresponding remuneration in accordance with their positions in the Group. The details of their remuneration will be disclosed in the annual report of the Company.

Save as disclosed in this announcement, each of the proposed Shareholder representative Supervisor and the employee representative Supervisors has confirmed that, as of the date of this announcement: (i) he/she has not held any other directorships in any listed companies, in Hong Kong or overseas, in the last three years, nor any other positions within the Group; (ii) he/she does not have any relationship with any Directors, Supervisors, senior management, substantial Shareholders or controlling Shareholders of the Company; (iii) he/she does not have any interests or short positions in the shares, underlying shares or bonds of the Company or its associated corporation(s) within the meaning of Part XV of the SFO; and (iv) there is no other information relating to his/her appointment that is required to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules and there is no other matter that needs to be brought to the attention of the Shareholders or the Stock Exchange.